Profile data is unavailable for this security.
About the company
Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
- Revenue in SEK (TTM)190.97m
- Net income in SEK-361.27m
- Incorporated2008
- Employees75.00
- LocationXbrane Biopharma ABRetzius Vag 8SOLNA 171 65SwedenSWE
- Phone+46 855905600
- Websitehttps://xbrane.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ascelia Pharma AB | 0.00 | -88.76m | 311.58m | 13.00 | -- | 5.12 | -- | -- | -2.63 | -2.63 | 0.00 | 1.80 | 0.00 | -- | -- | 0.00 | -65.17 | -- | -78.39 | -- | -- | -- | -- | -- | -- | -- | 0.2302 | -- | -- | -- | 16.72 | -- | -- | -- |
Lumito AB (publ) | 17.00k | -25.67m | 320.16m | 14.00 | -- | 2.95 | -- | 18,832.78 | -0.1244 | -0.1244 | 0.00008 | 0.4649 | 0.0001 | -- | 0.1491 | 1,133.33 | -21.11 | -20.77 | -23.47 | -22.38 | 70,276.65 | -- | -150,998.50 | -- | 0.928 | -167.26 | 0.0944 | -- | -- | -- | 4.56 | -- | -- | -- |
Annexin Pharmaceuticals AB (publ) | 0.00 | -46.41m | 320.85m | 4.00 | -- | 35.15 | -- | -- | -0.1765 | -0.1765 | 0.00 | 0.0171 | 0.00 | -- | -- | 0.00 | -256.08 | -125.42 | -351.79 | -151.33 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.17 | -- | -- | -- |
Medivir AB | 7.73m | -96.52m | 325.29m | 10.00 | -- | 1.54 | -- | 42.06 | -1.46 | -1.46 | 0.1028 | 1.89 | 0.032 | -- | 1.56 | 773,300.00 | -40.00 | -28.91 | -47.20 | -34.77 | -888.81 | -467.42 | -1,248.18 | -675.96 | -- | -- | 0.0482 | -- | 73.16 | -20.39 | -0.6275 | -- | -47.96 | -- |
Lifecare ASA | 12.98m | -34.98m | 334.73m | 32.00 | -- | 4.18 | -- | 25.78 | -0.2454 | -0.2454 | 0.092 | 0.4163 | 0.1621 | -- | 4.90 | 408,943.10 | -43.60 | -40.00 | -49.97 | -45.26 | -- | -- | -269.03 | -175.53 | -- | -- | 0.1812 | -- | -40.88 | 30.29 | -101.74 | -- | -- | -- |
Guard Therapeutics Intrntnl AB (publ) | 0.00 | -87.91m | 341.57m | 6.00 | -- | 5.58 | -- | -- | -8.74 | -8.74 | 0.00 | 5.27 | 0.00 | -- | -- | -- | -75.10 | -69.56 | -91.32 | -78.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.4289 | -- | -- | -- |
Herantis Pharma Oyj | 0.00 | 3.18m | 356.11m | 10.00 | 123.71 | 6.63 | 112.03 | -- | 0.0126 | 0.0126 | 0.00 | 0.2344 | 0.00 | -- | -- | 0.00 | 4.31 | -80.46 | 6.16 | -104.37 | -- | -- | -- | -- | -- | -- | 0.0073 | -- | -- | -- | 103.00 | -- | -- | -- |
SynAct Pharma AB | 0.00 | -190.84m | 367.54m | 5.00 | -- | 2.08 | -- | -- | -5.65 | -5.65 | 0.00 | 4.28 | 0.00 | -- | -- | 0.00 | -71.43 | -125.17 | -79.52 | -151.70 | -- | -- | -- | -- | -- | -853.13 | 0.0033 | -- | -- | -- | -117.54 | -- | -- | -- |
Saniona AB | 20.71m | -83.30m | 408.24m | 23.00 | -- | 14.98 | -- | 19.71 | -1.09 | -1.09 | 0.2629 | 0.2451 | 0.1726 | -- | 5.63 | 900,521.80 | -69.41 | -59.16 | -127.89 | -70.15 | -136.88 | -970.05 | -402.20 | -1,483.55 | -- | -3.85 | 0.71 | -- | 10.19 | -21.05 | 54.71 | -- | -34.94 | -- |
Xbrane Biopharma AB | 190.97m | -361.27m | 412.96m | 75.00 | -- | 1.05 | -- | 2.16 | -1.33 | -1.58 | 0.6978 | 0.2577 | 0.2465 | 1.34 | 332.12 | 2,053,430.00 | -46.63 | -40.98 | -78.01 | -67.24 | 15.43 | -- | -189.18 | -364.40 | 1.43 | -31.13 | 0.3693 | -- | 314.33 | 63.42 | -91.10 | -- | 60.02 | -- |
Mendus AB (publ) | 0.00 | -107.06m | 417.98m | 28.00 | -- | 0.5329 | -- | -- | -1.59 | -1.59 | 0.00 | 15.57 | 0.00 | -- | -- | 0.00 | -16.09 | -18.84 | -17.35 | -20.21 | -- | -- | -- | -28,474.53 | -- | -150.86 | 0.0348 | -- | -100.00 | -- | 26.78 | -- | -- | -- |
Lytix Biopharma AS | 3.96m | -87.20m | 441.98m | 10.00 | -- | 7.12 | -- | 111.63 | -2.16 | -2.16 | 0.0981 | 1.26 | 0.0368 | -- | 0.4091 | 399,100.00 | -80.96 | -56.91 | -94.07 | -65.83 | -- | -- | -2,202.36 | -771.78 | -- | -- | 0.0095 | -- | -63.82 | 63.94 | -56.77 | -- | -- | -- |
Bergenbio ASA | 516.88k | -153.30m | 444.40m | 16.00 | -- | 330.18 | -- | 859.77 | -0.1849 | -0.1849 | 0.0003 | 0.0347 | 0.0047 | -- | 0.0485 | 20,840.00 | -139.81 | -66.15 | -275.19 | -78.74 | -- | -- | -29,658.54 | -11,419.44 | -- | -- | 0.00 | -- | -9.00 | -31.43 | 36.98 | -- | -- | -- |
Hamlet BioPharma AB | 0.00 | -33.41m | 472.73m | 7.00 | -- | 8.17 | -- | -- | -0.2326 | -0.2326 | 0.00 | 0.453 | 0.00 | -- | -- | -- | -63.45 | -83.52 | -69.09 | -107.84 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -18.87 | -- | 78.01 | -- |
Initiator Pharma A/S | 0.00 | -34.30m | 499.28m | 3.00 | -- | 14.67 | -- | -- | -0.6301 | -0.6301 | 0.00 | 0.643 | 0.00 | -- | -- | 0.00 | -70.60 | -68.27 | -73.77 | -74.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
Oncopeptides AB | 39.17m | -245.79m | 534.95m | 62.00 | -- | -- | -- | 13.66 | -1.93 | -1.93 | 0.3085 | -0.0664 | 0.1517 | -0.2669 | 0.8075 | 687,157.90 | -95.16 | -141.28 | -135.11 | -200.49 | 102.05 | -- | -627.53 | -2,689.06 | 2.33 | -- | 1.06 | -- | 321.54 | -- | 26.29 | -- | -- | -- |
Data as of Jul 05 2024. Currency figures normalised to Xbrane Biopharma AB's reporting currency: Swedish Krona SEK
5.92%Per cent of shares held by top holders
Holder | Shares | % Held |
---|---|---|
Handelsbanken Fonder ABas of 31 May 2024 | 51.18m | 3.37% |
Swedbank Robur Fonder ABas of 29 May 2024 | 15.20m | 1.00% |
Teknik Innovation Norden Fonder ABas of 31 Dec 2022 | 13.70m | 0.90% |
SEB Investment Management ABas of 31 May 2024 | 7.60m | 0.50% |
Skandia Investment Management ABas of 30 Apr 2024 | 1.13m | 0.07% |
FCG Fonder ABas of 31 Dec 2023 | 659.32k | 0.04% |
Storebrand Asset Management ASas of 31 Jan 2024 | 316.72k | 0.02% |
SSgA Funds Management, Inc.as of 05 Jun 2024 | 102.28k | 0.01% |
WBS H�nicke Verm�gensverwaltung GmbHas of 31 Mar 2024 | 85.00k | 0.01% |
Danske Bank A/S (Investment Management)as of 31 May 2024 | 66.66k | 0.00% |
More ▼
Data from 31 Dec 2022 - 31 May 2024Source: FactSet Research Systems Inc.